Composition for preventing or treating non small cell lung cancer harboring the EGFR mutations

摘要

The present invention relates to a composition for preventing, improving or treating EGFR-mutated non-small cell lung cancer, which includes a JNK (c-Jun N-terminal kinase) activator as an active ingredient. The composition for preventing, improving or treating EGFR-mutated non-small cell lung cancer of the present invention is useful for the prevention, improvement or treatment of non-small cell lung cancer by significantly reducing the EGFR level of EGFR-mutated non-small cell lung cancer cells to induce apoptosis. Can be used. In particular, it is possible to effectively treat and prevent non-small cell lung cancer that gefitinib or erlotinib does not work. In addition, the composition for inhibiting resistance of non-small cell lung cancer to an EGFR tyrosine kinase inhibitor of the present invention effectively overcomes resistance to an EGFR tyrosine kinase inhibitor.